Lexicon Pharma (LXRX) Presents Phase 2a Top-Line Data for LX2931 in Pateints with RA
Tweet Send to a Friend
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced the following top-line results from a LX2931 phase 2a study in patients with rheumatoid ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
